Tuesday, April 13, 2010
The FDA has proposed amendments to its regulations on direct-to-consumer prescription drug advertising. Mass Tort Defense reports that:
The new proposal would require disclosure of the major side effects and contraindications of the drug in a clear, conspicuous, and neutral manner, regardless of the manner in which effectiveness information is presented in the advertisement.
Full story at Mass Tort Defense.